## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Peter J. Sims

Serial No:

09/090,393

Filed:

February 9, 1998

Examiner:

Art Unit:

B. Celsa

For:

COMPOSITIONS AND METHODS TO INHIBIT FORMATION

OF THE C5B-9 COMPLEX OF COMPLEMENT

**Assistant Commissioner for Patents** 

Washington, D.C. 20231

Response to Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, Amendment and Declaration under 37 C.F.R. § 1.821 (f)

Sir:

Responsive to the Notice to Comply with Requirements for Patent Applications

Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed on 4 February

1999, in the above-identified application, Applicant encloses a 3 & 1/2" diskette containing a

computer-readable form of the Sequence Listing, as well as a paper copy of the Sequence

Listing. The paper copy of the Sequence Listing is identical to the Sequence Listing that was

previously filed in the application and is not intended to replace the original Sequence Listing.

Applicant also encloses a copy of the Notice to Comply with Requirements for Patent

Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures,

U.S.S.N.: 09/020,393

Filed: February 9, 1998

Response to Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures,

Amendment and Declaration under 37 C.F.R. § 1.821 (f)



Declaration under 37 C.F.R. § 1.821(f)

I declare that the material on the diskette is identical to the enclosed paper copy of the Sequence Listing and the sequences as filed in the application on 9 February 1998, that the Sequence Listing does not add new matter to the application, and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Respectfully submitted,

Patrea L. Pabst

Reg. No. 31,284

Dated: March 4, 1999

ARNALL GOLDEN & GREGORY, LLP 2800 One Atlantic Center 1201 West Peachtree Street Atlanta, Georgia 30309-3450 (404) 873-8796 (404) 873-8797 (fax) U.S.S.N.: 09/020,393

Filed: February 9, 1998

Response to Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures,

Amendment and Declaration under 37 C.F.R. § 1.821 (f)

## Certificate of Mailing under 37 CFR § 1.8(a)

I hereby certify that this Response to Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, Amendment and Declaration under 37 C.F.R. § 1.821 (f), along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Jean Sichs
Jean Hicks

Date: March 4, 1999

Application No. 09 / 020, 3 9 3

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

	1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.	
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).	
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(	(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached marked-up copy of the "Raw Sequence Listing."	
P	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).	
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).	
	7. Other:	
App	licant must provide:	
中中中	An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"  An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification  A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)	0
For	questions regarding compliance with these requirements, please contact:	
For I	Rules Interpretation, call (703) 308-1123	

Please return a copy of this notice with your response.

For CRF submission help, call (703) 308-4212 For Patentin software help, call (703) 308-6856